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Editorial on the Research Topic
Comorbidity Burden in Rheumatic Diseases
The growing need to deliver more tailored and holistic patient care for people living with long-
term rheumatic and musculoskeletal diseases (RMDs), has marked the onset of a new era in
rheumatology. The shift away from the RMD itself as the “index” disease toward a focus on
the patient living with RMD along with other comorbidities i.e., multimorbidity defined as the
coexistence of two or more chronic diseases in the same individual (1), has placed emphasis on
the importance of preventing, screening, and managing comorbidities in order to improve patient
care. The concepts of multimorbidity and comorbidity both refer to a patient with more than
one disease, but from a different perspective and are not mutually exclusive or contradictory
(1). Whereas, comorbidity focuses on the index disease, addressing the co-occurrence of any
distinct additional entities, in multimorbidity no index disease is defined and all morbidities
are regarded of equal importance. An increasing body of evidence suggests that comorbidities
jeopardize the achievement of treat-to-target goals and are a barrier to optimal treatment outcomes,
an observation primarily originating from inflammatory arthritis studies including those in
rheumatoid arthritis (RA) (2–5) and spondyloarthritides (SpA) (6, 7).
The appreciation of the importance in appropriately identifying and managing comorbidities
in the routine care of people with RMDs, is the rationale for this themed issue. Through a
series of articles that address key aspects relating to prevalence and screening of comorbidities in
RMDs and impact on disease outcomes, this issue aims to inform the reader of the multi-faceted
aspects of various comorbidities in RMDs. Methodological aspects relating to the assessment
of comorbidities and their collective burden on disease outcomes are also discussed, aimed at
informing the reader of available “tools” for recording and addressing comorbidities for clinical
and research/epidemiological purposes.
Cardiovascular disease (CVD) in systemic rheumatic diseases represents an important
comorbidity seen even in the absence of traditional cardiovascular (CV) risk factors and adding
to the morbidity and mortality burden (8). Yet, CVD unfortunately remains poorly addressed in
many rheumatology clinics. In the first article of this issue, Atzeni et al. discuss non-invasive and
invasive techniques of investigating CVD including coronary artery disease (CAD), valve and other
morphological and structural abnormalities. The techniques described range from trans-thoracic
echocardiography to speckle Tracking Echocardiography (STE) to Positron Emission Tomography
(PET) and three-dimensional ultrasound and demonstrate the spectrum of modalities currently
available to assess CV morbidity. The article indicates the need for additional data before some of
these modalities are applied in routine clinical practice, despite the improved diagnostic accuracy
with some of the newer techniques.
Nikiphorou et al. Editorial: Comorbidity Burden in Rheumatic Diseases
Remaining on the topic of CVD in RMDs, Soulaidopoulos
et al. discuss the role of statins in RA, highlighting the complex
interplay between traditional risk factors (dyslipidaemia,
insulin resistance, arterial hypertension, obesity, smoking),
chronic inflammation and the development of premature
atherosclerosis. The article discusses the potential beneficial
impact of statins on RA disease activity, attributable to
their anti-inflammatory and immunomodulatory properties,
presenting the relevant literature. At the same time, the article
discusses that while the use of statins is widely advocated
in view of their crucial role in primary and secondary CVD
prevention strategies, data on the precise benefit of such
therapy in patients with RA are limited. The influence on
lipid metabolism through systemic inflammation and anti-
inflammatory treatments leads to variable states of dyslipidaemia
in RA and results in differing indications for statin use across RA
patients (9).
Rodríguez-Carrio et al. take a further leap into the realm
of dyslipidaemia in immune-driven diseases, characterized by
either decreased HDL levels or impaired HDL functionality.
Altered HDL levels and blood lipids have been described
in systemic autoimmune diseases, and the authors refer
that the “paradoxical” effect on CV risk (the so-called
“lipid paradox,” whereby low lipid levels are associated with
increased CV risk) is widely accepted albeit poorly understood
(10). Through appraising a broad range of immune-driven
conditions, the study confirms that anti-HDL antibodies
are a common hallmark in autoimmunity, especially in
systemic diseases such as mixed connective tissue disease
(MCTD) or ANCA-associated vasculitis. In addition, anti-
HDL antibodies interplay with disease-related autoantibodies
to account for the impaired antioxidant activity of HDL in
these conditions. The study adds to the growing literature
base on lipoprotein dysfunction and raises the potential
usefulness of anti-HDL antibodies as emerging biomarkers for
the unmet clinical need of CV risk stratification in these
conditions.
Risk stratification in RMDs represents an exciting new avenue,
with major research studies focusing on the identification
and performance of various biomarkers in disease. The
presence of cyclic citrullinated peptide (CCP) antibody in
RA is known to predict the development of disease up to
a decade before its actual onset and is also an indicator
of more aggressive disease (11). Twigg et al. attempt to
compare comorbidities in a cohort of CCP positive individuals
without or prior to onset of inflammatory arthritis using
the IACON cohort [the Inflammatory Arthritis CONtinuum
study (IACON)]. Interestingly, no significant difference in
comorbidities was observed among people with CCP antibodies
without inflammatory arthritis, compared to those of patients
with established inflammatory arthritis. The results of this
study indicate that comorbidities in inflammatory arthritis
may begin to accumulate before the onset of clinically
apparent inflammation. Such information is useful and
emphasizes yet again the importance of early screening for
comorbidities.
Moving into SpA, Moltó and Nikiphorou discuss common
comorbidities based on multinational epidemiological data
raising awareness on the subject, this time in SpA. The
article highlights the need for bridging the gap between
recommendations for managing comorbidities and actual
implementation in clinical practice. Osteoporosis and CVD
are among the commonest reported comorbidities in SpA,
an observation that may in part represent the outcome of
differing screening processes and reporting of comorbidities.
Aslam and Khan touch on this very issue, discussing how
the lack of a gold standard in measuring and recording
comorbidity and its burden on disease outcomes has resulted
in specific indices being developed in recent years for use
in RMDs. Such examples include the Rheumatic Disease
Comorbidity Index (RDCI) (12) and Multimorbidity Index
(MMI) (13). These indices have been developed primarily for
research purposes and this article reflects how the study of
comorbidities is critical in research, also in informing clinical
practice.
Finally, shifting into other systemic autoimmune diseases
and comorbidities, Alunno et al. remind us of lymphoma
and lymphomagenesis in primary Sjogren’s syndrome (pSS),
important extra-glandular manifestations of disease that worsen
prognosis. Non-Hodgkin’s lymphoma is one of the commonest
reported comorbidities in patients with pSS. Over the last 40
years, a consistent number of studies have attempted to identify
clinical, serological, and histological predictors of lymphoma
in pSS patients, but although progress has been made in this
field, many aspects remain to be fully elucidated. Several clinical,
serological, and histopathological features have been proposed
as predictive for lymphoma in pSS patients, allowing early
diagnosis and consequently, better management and prognosis.
This review article encompasses the body of evidence published
so far in this field highlighting the challenges and pitfalls of
different biomarkers within clinical practice. It also provides an
overview of epidemiological data, diagnostic procedures, and
evidence-based treatment strategies for NHL in pSS. The article
highlights that in clinical practice, clinicians should be alert
to patients displaying clinical and serological features such as
low C4 and persistent parotid gland enlargement. On the other
hand, the possible association between histological evidence
of germinal centers in salivary gland tissue and lymphoma
development remains to be defined.
In conclusion, we hope that this themed issue increases
awareness into comorbidities in RMDs and their importance,
both from a clinical, but also epidemiological perspective.
Comorbidities add to the burden of disease and should form a
core part of the management of people with RMDs in routine
clinical care, with emphasis placed on early recognition and
management.
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